TIDMAZN

RNS Number : 2841T

AstraZeneca PLC

02 July 2018

02 July 2018 15:00 BST

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2018 the issued share capital of AstraZeneca PLC with voting rights is 1,266,663,838 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,266,663,838.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Relations 
 Karen Birmingham       UK/Global                     +44 203 749 5634 
 Rob Skelding           UK/Global                     +44 203 749 5821 
 Matt Kent              UK/Global                     +44 203 749 5906 
 Gonzalo Viña      UK/Global                     +44 203 749 5916 
 Jacob Lund             Sweden                        +46 8 553 260 20 
 Michele Meixell        US                             +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                  +44 203 749 5712 
 Josie Afolabi                                        +44 203 749 5631 
 Craig Marks            Finance; Fixed Income; M&A    +44 7881 615 764 
 Henry Wheeler          Oncology                      +44 203 749 5797 
 Mitchell Chan          Oncology; Other                +1 240 477 3771 
 Christer Gruvris       Brilinta; Diabetes            +44 203 749 5711 
 Nick Stone             Respiratory; Renal            +44 203 749 5716 
 Jennifer Kretzmann     Retail Investors              +44 203 749 5824 
 US toll-free                                          +1 866 381 7277 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRLLFVFDSIFIIT

(END) Dow Jones Newswires

July 02, 2018 10:00 ET (14:00 GMT)

Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Astrazeneca